Cargando...
Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
Resistance to targeted therapy is an ongoing problem for the successful treatment of Stage IV metastatic melanoma. For many patients, the use of targeted therapies, such as BRAF kinase inhibitors, were initially promising yet resistance inevitably occurred. Even after combining BRAF kinase inhibitor...
Gardado en:
| Publicado en: | Oncotarget |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5650456/ https://ncbi.nlm.nih.gov/pubmed/29088901 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18523 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|